Expression and regulation of IFNα/β receptor in IFNβ-treated patients with multiple sclerosis

Neurology

Volumn 71, Issue 24, 2008, Pages 1940-1947

  Gilli, F ^a   Valentino, P ^a   Caldano, M ^a   Granieri, L ^a   Capobianco, M ^a   Malucchi, S ^a   Sala, A ^a   Marnetto, F ^a   Bertolotto, A ^a  

^a SAN LUIGI GONZAGA HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA BETA INTERFERON RECEPTOR; BETA INTERFERON; ISOPROTEIN; MESSENGER RNA; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; IMMUNOLOGIC FACTOR;

ANTIBODY SCREENING; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; TREATMENT DURATION; ALTERNATIVE RNA SPLICING; CELL MEMBRANE; CHEMISTRY; DOWN REGULATION; DRUG EFFECT; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HOMEOSTASIS; IMMUNOLOGY; METABOLISM; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; PROTEIN TERTIARY STRUCTURE; RETROSPECTIVE STUDY; UPREGULATION;

ALTERNATIVE SPLICING; CELL MEMBRANE; DOWN-REGULATION; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; HOMEOSTASIS; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PROTEIN ISOFORMS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, INTERFERON ALPHA-BETA; RETROSPECTIVE STUDIES; RNA, MESSENGER; UP-REGULATION;

EID: 58149395972     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000327340.50284.8d     Document Type: Article

References (37)

1. Rio J, Nos C, Tintore M, et al. Defining the response to interferon-beta in relapsing-remitting multiple sclerosis patients. Ann Neurol 2006;59:344-352.
2. Uze G, Luftalla G, Morgensen KE. α and β interferons and their receptors and their friends and relations. J Interferon Cytokine Res 1995;15:3-26.
3. Cleveland MG, Lane RG, Klimpel GRR. Enhanced IFN-α/β and defective IFN-γ production in chronic GVHD: a potential mechanism for immunosuppression. Cell Immunol 1987;110:120-130.
4. Zoon KC, Arnheiter H, Nedden DZ, Fitzgerald DJP, Willingham MC. Human interferon alpha enters cells by receptor-mediated endocytosis. Virology 1989;130:195-203.
5. Lau AS, Hannigan GE, Freedman MH, Williamo BRG. Regulation of interferon receptor expression in human blood lymphocytes in vitro and during interferon therapy. J Clin Invest 1986;77:1632-1638.
6. Billard C, Ferbus D, Diez RA, et al. Correlation between the biological and therapeutic effects of interferon-alpha in low-grade nodular non-Hodgkin's lymphoma: lack of in vivo down-regulation and reduced affinity of IFN-alpha receptors in unresponsive patients. Leuk Res 1991;15: 121-128.
7. Oliver B, Mayorga C, Fernandez V. Interferon receptor expression in multiple sclerosis patients. J Neuroimmunol 2007;183:225-231.
8. Bertolotto A, Gilli F, Sala A, et al. Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients. Neurology 2003;60:634-639.
9. Deisenhammer F, Reindel M, Harvey J, Gasse T, Dilitz E, Berger T. Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies. Neurology 1999;52:1239-1243.
10. Malucchi S, Sala A, Gilli F, et al. Neutralizing antibodies reduce the efficacy of betaIFN during treatment of multiple sclerosis. Neurology 2004;62:2031-2037.
11. Kappos L, Clanet M, Sandberg-Wollheim M, et al. European Interferon Beta-1a IM Dose-Comparison Study Investigators. Neutralising antibodies and efficacy of interferon beta-1a: a 4-year controlled study. Neurology 2005;65:40-47.
12. Francis GS, Rice GP, Alsop JC, PRISMS Study Group. Interferon beta-1a in MS: results following development of neutralizing antibodies in PRISMS. Neurology 2005;65: 48-55.
13. Sorensen PS, Deisenhammer F, Duda P, et al. for the EFNS Task Force on Anti-IFNβ Antibodies in Multiple Sclerosis. Guidelines on use of anti-IFNβ antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFNβ antibodies in multiple sclerosis. Eur J Neurol 2005;12:817-827.
14. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
15. WHO Expert Committee on Biological Standardisation. Thirty-Fifth Report. WHO Technical Report Series 725. Geneva: World Health Organization; 1985.
16. Kawade Y. Quantitation of neutralization of interferon by antibody. Meth Enzymol 1986;119:558-573.
17. Kawade Y, Finter N, Grossberg SE. Neutralization of the biological activity of cytokines and other protein effectors by antibody: theoretical formulation of antibody titration curves in relation to antibody affinity. J Immunol Methods 2001;278:127-144.
18. Grossberg SE, Kawade Y, Kohase M, Klein JP. The neutralization of interferons by antibody, II: neutralizing antibody unitage and its relationship to bioassay sensitivity -the tenfold reduction unit J Interferon Cytokine Res 2001; 21:743-755.
19. Vallittu AM, Halminen M, Peltoniemi J, et al., the Finnish Beta-Interferon Study Group. Neutralizing antibodies reduce MxA protein induction in interferon beta-1a-treated MS patients. Neurology 2002;58:1786-1790.
20. Vallittu AM, Salmi AA, Eralinna JP, the Finnish Beta-Interferon Study Group. MxA protein induction in MS patients treated with intramuscular IFNbeta-1a. Neurol Sci 2006;26:438-443.
21. Gniadek P, Aktas O, Wandinger KP, et al. Systemic IFN-beta treatment induces apoptosis of peripheral immune cells in multiple sclerosis patients. J Neuroimmunol 2003; 137:187-196.
22. Gilli F, Bertolotto A, Sala A, et al. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs. Brain 2004; 127(pt 2):259-268.
23. Mathurin P, Xiong S, Kharbanda KK, et al. IL-10 receptor and coreceptor expression in quiescent and activated hepatic stellate cells. Am J Physiol Gastrointest Liver Physiol 2002;282:G981-G990.
24. Sundaresan S, Roberts PE, King KL, Sliwkowski MX, Mather JP. Biological response to ErbB ligands in non-transformed cell lines correlates with a specific pattern of receptor expression. Endocrinology 1997;139:4756-4764.
25. Hardy MP, Owczarek CM, Trajanovska S, Liu X, Kola I, Hertzog PJ. The soluble murine type I interferon receptor Ifnar-2 is present in serum, is independently regulated, and has both agonistic and antagonistic properties. Blood 2001;97:473-482.
26. Gauzzi MG, Canini I, Eid P, Belardelli F, Gessani S. Loss of type I IFN receptors and impaired IFN responsiveness during terminal maturation of monocyte-derived human dendritic cells. J Immunol 2002;169:3038-3045.
27. Dupont SA, Goelz S, Goyal J, Green M. Mechanisms for regulation of cellular responsiveness to human IFN-beta 1a. J Interferon Cytokine Res 2002;22:491-501.
28. Colamonici O, Yan H, Domanski P. Direct binding to and tyrosine phosphorylation of the alpha subunit of the type I interferon receptor by p135tyk2 tyrosine kinase. Mol Cell Biol 1994;14:8133-8142.
29. Fantuzzi L, Eid P, Malorni W, et al. Post-translational up-regulation of the cell surface-associated component of the human type I interferon receptor during differentiation of peripheral blood monocytes: role in the biological response to type I interferon. Eur J Immunol 1997;27:1075.
30. Youssef S, Maor G, Wildbaum G, Grabie N, Gour-Lavie A, Karin N. C-C chemokine-encoding DNA vaccines enhance breakdown of tolerance to their gene products and treat ongoing adjuvant arthritis. J Clin Invest 2000;106: 361-371.
31. Salomon I, Netzer N, Wildbaum G, Schif-Zuck S, Maor G, Karin N. Targeting the function of IFN-gamma-inducible protein 10 suppress ongoing adjuvant arthritis. J Immunol 2002;169:2685-2693.
32. Wildbaum G, Netzer N, Karin N. Tr1 cell-dependent active tolerance blunts the pathogenic effects of determinant spreading. J Clin Invest 2002;110:701-710.
33. Wildbaum G, Nahir MA, Karin N. Beneficial autoimmunity to proinflammatory mediators restrains the consequences of self-destructive immunity. Immunity 2003;19: 679-688.
34. Schellekens H. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat Rev Drug Discov 2002;1:457-462.
35. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
36. McKeage K, Wagstaff AJ. Subcutaneous interferon-beta1a: new formulation. CNS Drugs 2007;21:871-876.
37. Giovannoni G, Barbarash O, Casset-Semanaz F, et al., RNF Study Group. Immunogenicity and tolerability of an investigational formulation of interferon-beta 1a: 24- and 48-week interim analyses of a 2-year, single-arm, historically controlled, phase IIIb study in adults with multiple sclerosis. Clin Ther 2007;29:1128-1145.